Understanding Myelodysplastic Syndromes (MDS): Symptoms, Triggers, and Treatment Options

Myelodysplastic Syndromes (MDS) are a complex group of bone marrow disorders affecting the production of healthy blood cells. Because of their diversity, potential progression, and impact on patients’ quality of life, greater awareness of MDS, including its symptoms, causes, diagnosis, and treatment, is important. This blog highlights what is currently known about symptoms, causes, diagnosis, and treatment options for MDS

Key Statistics and Epidemiology

• In the United States, there are an estimated 10,000 new cases of MDS each year, with some estimates much higher.
  
• The number of people living with MDS in the U.S. is estimated to be between 60,000 and 170,000, depending on how cases are diagnosed and reported.
  
• MDS is mostly a disease of older adults: the median age at diagnosis is about 73 years.
  
• Men are twice as likely to develop MDS as women.
  

These numbers indicate both the seriousness of MDS for older populations, and that diagnoses may be increasing in part due to better detection and aging demographics. PMC+1

What Is MDS?

Myelodysplastic Syndromes are disorders in which the bone marrow, the body’s blood cell factory, does not function properly. In MDS:

• Blood stem cells may acquire genetic mutations.
  
• The bone marrow may fail to produce sufficient numbers of functional red blood cells, white blood cells, or platelets.
  
• Ineffective blood cells may be produced, or precursors that do not mature properly.
  

MDS can be considered a form of blood cancer, though how fast it progresses and how severe it becomes varies widely among individuals. Some cases remain relatively stable over many years; others progress more rapidly, sometimes evolving into acute myeloid leukemia (AML).

Symptoms of MDS

Because MDS affects blood cell production, its symptoms relate to reduced numbers or function of those cells. Common symptoms include:

• Anemia signs: fatigue, weakness, shortness of breath, pale skin, dizziness.
  
• Bleeding or clotting issues: easy bruising, frequent or prolonged nosebleeds, bleeding gums, petechiae (small red or purple spots on skin), heavy menstrual periods.
  
• Infection risk: frequent infections, fevers, sore throat, persistent cough, often because white blood cell counts or function are impaired.
  
• Other possible symptoms: bone pain, enlarged spleen or liver, swollen lymph nodes.
  

Symptoms often develop gradually. Because many signs, such as fatigue, are non-specific, diagnosis may be delayed. Diagnostic tests are required to confirm a case of MDS.

What Causes MDS?

The precise causes of MDS are not fully understood, but several risk factors and contributing factors have been identified:

• Genetic mutations: Changes or mutations in certain genes are commonly found in MDS cells and disrupt the normal development of blood cells.
  
• Previous chemotherapy or radiation therapy: Treatment for other cancers can damage bone marrow cells, leading to therapy-related MDS.
  
• Exposure to certain chemicals: Benzene, pesticides, heavy metals and other environmental toxins have been associated with elevated risk.
  
• Age: Older age is one of the strongest risk factors. The risk increases significantly after age 60.
  
• Other medical conditions and inherited predisposition: Some genetic syndromes can increase risk; also, people with prior bone marrow disorders may be more vulnerable.

Diagnosing MDS

Diagnosis typically involves several steps to understand how the disease is affecting blood production and marrow health:

1. Blood tests – complete blood count (CBC) with differential, to detect low or abnormal red cells, white cells, or platelets.
   
2. Bone marrow biopsy and aspiration – to examine the marrow for cellularity, presence of abnormal precursor cells (“blasts”), and other morphology.
   
3. Cytogenetic and molecular testing – to identify chromosomal abnormalities (for example, deletions or translocations) or gene mutations, which help determine risk category.
   
4. Risk stratification – Systems such as Revised International Prognostic Scoring System (IPSS-R) or other prognostic scoring help classify patients into lower-risk or higher-risk categories, which in turn influences treatment approach.

Prognosis and Outcomes

• Long-term survival depends heavily on risk category, age, fitness, genetic findings, and whether a stem cell transplant is an option.
  
• Hematopoietic stem cell transplant has the potential to cure MDS in some patients. In certain cases, 30% to 70% of patients who undergo transplant may achieve long-term survival.
  
• A comparative study found that patients who were assigned to a donor stem cell transplant had ~47.9% survival at three years, compared with about 26.6% for those without a donor at the same time points.
  

Even for those not eligible for transplant, treatments can improve quality of life, reduce symptoms, and sometimes slow disease progression.

Treatment Options

Management of MDS is often individualized, based on symptoms, risk classification, patient age, and overall health. Some of the main treatment approaches include:

1. Supportive care
   
   • Blood transfusions (red cell or platelets) to relieve symptoms like anemia or bleeding.
     
   • Growth factors (e.g., erythropoietin, G-CSF) to stimulate production of certain blood cells.
     
   • Antibiotics or antifungals to prevent or treat infections.
     
   • Careful monitoring of blood cell counts and preventative measures for complications.
     
2. Drug therapies
   
   • Hypomethylating agents (e.g., azacitidine, decitabine) are often used for patients with moderate or higher risk.
     
   • Other drugs: immunomodulatory agents, immunosuppressive therapy in selected cases.
     
3. Hematopoietic Stem Cell Transplantation (HSCT)
   
   • The only treatment with curative potential for many patients.
     
   • Best outcomes are seen in younger, fitter individuals with compatible donors, favorable genetic risk, and when the disease is in a less advanced stage.
     
   • Risks include graft-versus-host disease, transplant-related mortality, infections, and long recovery periods.
     
4. Clinical trials and investigational therapies
   
   • Participation in clinical trials can offer access to newer treatments, combinations, or approaches not yet approved.
     
   • These may include novel agents targeting specific mutations, novel transplant conditioning regimens, or supportive care innovations.

Living with MDS

Because MDS is a chronic condition with variable severity and progression, some daily-life and care considerations are often part of the journey:

• Regular follow-ups with hematologists or oncologists. Monitoring is key.
  
• Managing symptoms: fatigue, infections, bleeding, etc., often with supportive therapies.
  
• Nutritional support, maintaining physical activity as tolerated.
  
• Mental health: because a diagnosis of MDS, especially higher risk, can have emotional and psychological impacts. Peer networks or patient advocacy organizations may be helpful.

Emerging Research & Future Directions

• Improved genetic and molecular profiling helps refine risk stratification, enabling more tailored therapies.
  
• Research is ongoing into new drugs and agents targeting specific mutations, epigenetic modifiers, and immune-based therapies.
  
• Optimizing transplant approaches: safer conditioning regimens, better donor matching, reducing complications.
  
• Efforts are underway to detect MDS earlier, perhaps in people with unexplained anemia, so interventions can begin before symptoms worsen.

Frequently Asked Questions (FAQs)

Q: Can MDS be cured?
A: For some patients, especially those who undergo a stem cell transplant under favorable conditions, cure is possible. However, transplant is not suitable or safe for everyone.

Q: How long do people with MDS live?
A: Survival varies widely. Lower-risk MDS may have a life expectancy of several years (often 3-10 years or more), while higher-risk forms may progress rapidly with shorter expected survival times. Outcomes also hinge on age, comorbidities, genetic risk, and treatment choices. 

Q: What determines risk in MDS?
A: Key factors include genetic/cytogenetic abnormalities, proportion of immature (“blast”) cells in bone marrow, cytopenias (levels of red cells, white cells, platelets), patient age/health, and how rapidly changes are occurring.

Q: Is there anything people can do to reduce risk or catch MDS earlier?
A: While many risk factors (like age or previous cancer therapy) are not modifiable, minimizing exposure to known environmental toxins (e.g., benzene), careful monitoring after cancer treatment, and seeking evaluation for unexplained anemia or abnormal blood counts may help with earlier detection.

Moving Forward with MDS Research

As understanding of Myelodysplastic Syndromes continues to grow, so do opportunities to improve prevention, diagnosis, and treatment. Ongoing clinical research plays an essential role in shaping the future of care and expanding options for patients.

For those who want to stay informed about current studies, you can explore Leapcure’s MDS research registry for information on ongoing clinical trials and studies. Additional resources such as the MDS Foundation and the American Cancer Society provide further insights into symptoms, risk factors, and treatment updates.

Together, these resources offer pathways to learn more about MDS and the ongoing efforts to improve outcomes through research.